ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AMRN Amarin Corp PLC

0.8652
0.0259 (3.09%)
Last Updated: 16:42:03
Delayed by 15 minutes
Name Symbol Market Type
Amarin Corp PLC NASDAQ:AMRN NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.0259 3.09% 0.8652 0.8644 0.8659 0.8693 0.813 0.813 318,579 16:42:03

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corp. plc & En...

27/02/2019 7:25pm

Business Wire


Amarin (NASDAQ:AMRN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Amarin Charts.

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amarin Corporation plc (“Amarin” or “the Company”) (NASDAQ: AMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's shares between September 24, 2018 and November 9, 2018, inclusive (the "Class Period"), are encouraged to contact the firm before April 23, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Amarin touted the results of its REDUCE-IT trial for Vascepa, the Company’s cardiovascular disease drug candidate, while knowing the results were not as positive as it was representing them to be. The placebo given to the control portion of the trial may have led to an increased rate of cardiovascular events for those patients. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Amarin, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law FirmBrian Schall, Esq.,Sherin Mahdavian, Esq.,www.schallfirm.comOffice: 310-301-3335Cell: 424-303-1964info@schallfirm.com

1 Year Amarin Chart

1 Year Amarin Chart

1 Month Amarin Chart

1 Month Amarin Chart

Your Recent History

Delayed Upgrade Clock